BackBetter Therapeutics- Tradeable Rights - March 2021 Overview
Better Therapeutics Inc - Tradeable Rights - March 2021

Better Therapeutics- Tradeable Rights - March 2021 P/E Ratio

Latest P/E ratio for Better Therapeutics- Tradeable Rights - March 2021: 0.0 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

0.00

P/E Ratio

0.00

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) FAQ

As of the most recent data, MCADR shows a P/E ratio of 0.0. That is below the sector sector average of 27.12. Scroll down for historical charts and peer comparison views.

The its sector sector average P/E ratio is about 27.12. Better Therapeutics- Tradeable Rights - March 2021 is at 0.0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how MCADR stacks up against individual peers as well.

Investors watch MCADR's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Better Therapeutics- Tradeable Rights - March 2021's latest reading is 0.0. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this p/e ratio page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 0.0) with ownership activity and broader fundamentals.